EPS: CA$0.94 (down from CA$1.59 in 1Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed ...

Investors might want to bet on IGM Biosciences, Inc. (NASDAQ:IGMS), as it has been recently upgraded to a Zacks Rank #2 (Buy) ...

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops ...

IGM Financial Inc. (IGM or the Company) (TSX: IGM) today announced earnings results for the first quarter of 2024.

It said in a Securities and Exchange Commission filing earlier this year that it would continue to focus on cancer and ...

At his speech at the annual meeting, O’Sullivan said: “Today, IGM’s realigned business gives us a blueprint for meaningful ...

IGM Financial reveals earnings for the most recent quarter on May 2. Analysts on Wall Street predict IGM Financial will release earnings per share of CAD 0.889. Go here to follow IGM Financial stock ...

Wall Street expects a year-over-year increase in earnings on higher revenues when IGM Biosciences, Inc. (IGMS) reports results for the quarter ended March 2024. While this widely-known consensus ...

Sanofi's oncology pruning will lead to the evaporation of an estimated $3 billion in potential biobucks for partner IGM ...

April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the ...

Investors might want to bet on IGM Biosciences, Inc. (IGMS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...